María Inmaculada S. M.

Engaged in studies of systemic autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and Sjögren’s syndrome.

• Rheumatoid arthritis therapeutic optimization
• Psoriatic arthritis stratified by prior biologic exposure
• Sjögren’s syndrome with moderate‑to‑severe systemic activity
• Systemic lupus erythematosus renal involvement

Research emphasizes disease‑modifying agents and patient‑centered outcomes.

Broad oncology portfolio covering solid tumors and hematologic malignancies, including breast cancer subtypes, soft‑tissue sarcoma, acute myeloid leukemia, and multiple myeloma.

• Hormone‑receptor positive, HER2‑negative breast cancer targeted therapy
• Soft‑tissue sarcoma treatment sequencing
• Acute myeloid leukemia novel agents
• Multiple myeloma relapse prevention
• HER2‑positive breast cancer antibody‑drug conjugates

Efforts aim to enhance survival and address resistance mechanisms.

Investigations into viral infections, bacterial endocarditis, and transplant‑related immune modulation, notably human immunodeficiency virus and renal transplantation.

• HIV antiretroviral optimization
• Enterococcus faecalis infective endocarditis
• Kidney transplantation immunosuppression strategies
• Metabolic syndrome management in transplant candidates

Studies target long‑term graft function and infection control.

Research addressing atherosclerotic risk, obesity, and related metabolic disorders, with a focus on primary prevention and therapeutic innovation.

• Atherosclerotic cardiovascular disease primary prevention
• Obesity intervention trials
• Type 2 diabetes metabolic control
• Statin‑related genotyping safety

Objectives include reducing major adverse cardiovascular events and improving metabolic health.